VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Kachroo, S. [1 ]
Phatak, H. [1 ]
Dorian, P. [2 ]
Kongnakorn, T. [3 ]
Lanitis, T. [4 ]
Kuznik, A. [5 ]
Mardekian, J. [6 ]
Liu, X. [7 ,8 ]
Lawrence, J. [1 ]
Lip, G. Y. [9 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Evidera, Bangkok, Thailand
[4] Evidera, London, England
[5] Celgene Corp, Summit, NJ USA
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, New York, NY USA
[8] Univ Tennessee, Coll Pharm, Knoxville, TN USA
[9] Univ Birmingham, Birmingham, W Midlands, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.661
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV67
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Guo, W.
    Tian, X.
    Li, W.
    Han, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [42] Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
    Hallinen, Taru
    Soini, Erkki
    Asseburg, Christian
    Linna, Miika
    Eloranta, Pia
    Sintonen, Sari
    Kosunen, Mikko
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 745 - 755
  • [43] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [44] Cost-effectiveness of non-Vitamin-K oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation
    Harenberg, J.
    Krejczy, M.
    Wehling, M.
    Obermann, K.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1107 - 1107
  • [45] The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
    van Hulst, Marinus
    Stevanovic, Jelena
    Jacobs, Maartje S.
    Tieleman, Robert G.
    Kappelhoff, Bregt
    Postma, Maarten J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) : 38 - 46
  • [46] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [47] Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China
    Liu, Lin
    Hong, Dongsheng
    Ma, Kuifen
    Lu, Xiaoyang
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 658 - 668
  • [48] COST-EFFECTIVENESS ANALYSIS OF NEW ORAL ANTICOAGULANTS COMPARED TO WARFARIN IN THAI PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Dilokthornsakul, P.
    Nathisuwan, S.
    Krittayaphong, R.
    Chutinet, A.
    Permsuwan, U.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [49] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
    Kostas Athanasakis
    Eleftheria Karampli
    Dimitrios Tsounis
    Aikaterini Bilitou
    John Kyriopoulos
    [J]. Clinical Drug Investigation, 2015, 35 : 693 - 705
  • [50] Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
    Athanasakis, Kostas
    Karampli, Eleftheria
    Tsounis, Dimitrios
    Bilitou, Aikaterini
    Kyriopoulos, John
    [J]. CLINICAL DRUG INVESTIGATION, 2015, 35 (11) : 693 - 705
12345